Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial.
Ohkubo H, Kessoku T, Tanaka K, Takahashi K, Takatsu T, Yoshihara T, Misawa N, Ashikari K, Fuyuki A, Kato S, Higurashi T, Hosono K, Yoneda M, Misumi T, Shinoda S, Stanghellini V, Nakajima A. Ohkubo H, et al. Among authors: ashikari k. Biosci Microbiota Food Health. 2024;43(2):135-144. doi: 10.12938/bmfh.2023-080. Epub 2023 Dec 27. Biosci Microbiota Food Health. 2024. PMID: 38562545 Free PMC article.
Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol.
Yoshihara T, Kessoku T, Takatsu T, Misawa N, Ashikari K, Fuyuki A, Ohkubo H, Higurashi T, Iwaki M, Kurihashi T, Nakatogawa M, Yamamoto K, Terada I, Tanaka Y, Nakajima A. Yoshihara T, et al. Among authors: ashikari k. Contemp Clin Trials Commun. 2022 Oct 28;30:101019. doi: 10.1016/j.conctc.2022.101019. eCollection 2022 Dec. Contemp Clin Trials Commun. 2022. PMID: 36387985 Free PMC article.
Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
Higurashi T, Ashikari K, Tamura S, Saigusa Y, Takatsu T, Misawa N, Yoshihara T, Matsuura T, Fuyuki A, Ohkubo H, Kessoku T, Hosono K, Yoneda M, Nakajima A. Higurashi T, et al. Among authors: ashikari k. Cancer Prev Res (Phila). 2022 Oct 4;15(10):661-668. doi: 10.1158/1940-6207.CAPR-22-0049. Cancer Prev Res (Phila). 2022. PMID: 36083855 Clinical Trial.
47 results